SOURCE: AXM Pharma, Inc.

April 26, 2005 08:15 ET

AXM Pharma Signs $362,000 Distribution Agreements for Whisper Feminine Hygiene Products and Plant Update

LAS VEGAS, NV -- (MARKET WIRE) -- April 26, 2005 -- AXM Pharma, Inc. (AMEX: AXJ) announced today that it has signed a 2005 Distribution Agreement for $217,654 with Beijing Hengcheng for the Company's line of Whisper feminine hygiene products and a Distribution Agreement for $145,103 with Nanhai Junyun for the Company's line of Whisper feminine hygiene products.

The Whisper line includes Elegance Therapeutic Feminine Hygiene Wash, which is a feminine hygiene wash formulated with 8 herbal extracts and pH balanced. The product is positioned as a therapeutic wash to relieve vaginal itch and vaginitis and to sooth any vaginal irritation that may be present.

The Company also announced today that the plant in Shenyang is currently producing Asarone, Elegance and Lifcomf products. In addition, trial batches of Lifegate are being produced to become commercially available by May 1, 2005. The Sunkist product sales and the sales of Asarone, Elegance and Lifcomf products are swiftly ramping up. With the most recent financing completed, additional raw materials have been sourced and are in the process of being purchased in order to immediately begin delivering goods against existing backlogged purchase orders.

AXM Pharma Inc.,, through its wholly owned subsidiary, Werke Pharmaceuticals, Inc., is the 100% owner of AXM Pharma Shenyang, Inc. ("AXM Shenyang"), a Wholly Foreign Owned Enterprise ("WFOE") under the laws of the People's Republic of China. AXM Shenyang is located in the City of Shenyang, in the Province of Liaoning, China. AXM Shenyang and its predecessor company Shenyang Tianwei Pharmaceutical Factory, Ltd. ("STPF"), has an operating history of approximately 10 years. AXM Shenyang historically has been a manufacturer of proprietary and generic pharmaceutical products, which include injectables, capsules, tablets, liquids and medicated skin products for export and domestic Chinese sales. For additional information on AXM Pharma Inc, please visit or call Investor Communications Company, LLC at 866 562 0134.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this news release include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products and prices. With respect to AXM, except for the historical information contained herein, the matters discussed in this news release are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, AXM's extremely limited operating history, uncertainties related to the Company's access to additional capital, competition and dependence on key management.

Contact Information

  • Contact:
    Contact Information:
    Tom Bostic
    Investor Communications Company, LLC
    (866) 562-0134